Linee di indirizzo sul Mieloma Multiplo (aggiornamento 8 Agosto 2018) a cura Gruppo di Lavoro Regionale per l'appropriatezza p
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Manni Mohyuddin on Twitter: "The first randomized trial of CAR-T in multiple myeloma. https://t.co/7HSW4ihEZP Ide-cel versus a choice of five regimens for relapsed multiple myeloma! Lots to learn and process from this
![Re‐challenging with anti‐CD38 monotherapy in triple‐refractory multiple myeloma patients is a feasible and safe approach - Alici - 2016 - British Journal of Haematology - Wiley Online Library Re‐challenging with anti‐CD38 monotherapy in triple‐refractory multiple myeloma patients is a feasible and safe approach - Alici - 2016 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cb937bba-359f-42b3-8ab6-a4922e018b5b/bjh.2016.174.issue-3.cover.jpg?trick=1675173597736)
Re‐challenging with anti‐CD38 monotherapy in triple‐refractory multiple myeloma patients is a feasible and safe approach - Alici - 2016 - British Journal of Haematology - Wiley Online Library
![Manni Mohyuddin on Twitter: "The first randomized trial of CAR-T in multiple myeloma. https://t.co/7HSW4ihEZP Ide-cel versus a choice of five regimens for relapsed multiple myeloma! Lots to learn and process from this Manni Mohyuddin on Twitter: "The first randomized trial of CAR-T in multiple myeloma. https://t.co/7HSW4ihEZP Ide-cel versus a choice of five regimens for relapsed multiple myeloma! Lots to learn and process from this](https://pbs.twimg.com/media/FooQafZagAYoNVs.jpg)